Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 9:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,236 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Immunodeficiency Disease Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mobile Enhanced Prevention Support for People Leaving Jail

NCT04036396
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases, Bacterial, Hepatitis C, Substance Use Disorders
Interventions
Mobile Enhanced Prevention Support, Usual Care plus Customized Referrals
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Santa Fe Springs, California
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 20, 2026, 9:55 AM EDT
Completed Not applicable Interventional

Reducing Unsafe Alcohol Use in HIV-Positive Individuals

NCT00371969
View directory record Official record
Conditions
Alcohol Abuse
Interventions
Enhanced Motivational Interview, Standard Motivational Interview or viewing DVD
Behavioral
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Sep 20, 2026, 9:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Anti-HIV Activity of Capravirine Alone and in Combination With Other Anti-HIV Drugs

NCT00005673
View directory record Official record
Conditions
Healthy, HIV Infection
Interventions
Capravirine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 20, 2026, 9:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

HIV, Abuse, and Psychiatric Disorders Among Youth

NCT00603369
View directory record Official record
Conditions
HIV Infections
Interventions
group intervention
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
13 Years to 19 Years
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2007
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 5, 2009 · Synced Sep 20, 2026, 9:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

"Prime-Boost" Vaccine Schedule for Prevention of HIV Infection

NCT00109629
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA016-00-VP, VRC-HIVADV014-00
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 20, 2026, 9:55 AM EDT
Completed No phase listed Observational

Long-term Follow-up of HIV Infected Patients Identified During Early Infection

NCT00086372
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2012 · Synced Sep 20, 2026, 9:55 AM EDT
Completed Not applicable Interventional

An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies

NCT00002272
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Foscarnet sodium
Drug
Lead sponsor
Astra USA
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 20, 2026, 9:55 AM EDT
Completed Phase 1 Interventional

Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection

NCT00000739
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Dapsone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Month to 12 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
43
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 20, 2026, 9:55 AM EDT
Completed No phase listed Observational

Immunoglobulin G Therapy Dose Optimization

NCT04818177
View directory record Official record
Conditions
Obesity, Immune Deficiency
Interventions
Institutional standard intravenous immune globulin treatment
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Somerville, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 20, 2026, 9:55 AM EDT
Completed Phase 4 Interventional Results available

Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)

NCT02519777
View directory record Official record
Conditions
HIV Infections
Interventions
Placebo for maraviroc (MVC), Placebo for dolutegravir (DTG), Dolutegravir (DTG), Maraviroc (MVC)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
23
States / cities
Los Angeles, California • San Diego, California • Torrance, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Sep 20, 2026, 9:55 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults

NCT00071851
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA009-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 20, 2026, 9:55 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care

NCT03227861
View directory record Official record
Conditions
HIV-1
Interventions
DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
16
States / cities
Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 20, 2026, 9:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together

NCT00352066
View directory record Official record
Conditions
HIV Infection
Interventions
apricitabine
Drug
Lead sponsor
Avexa
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Sep 20, 2026, 9:55 AM EDT
Completed Not applicable Interventional

Feasibility of Using a Structured Daily Diary

NCT01953653
View directory record Official record
Conditions
HIV Infection
Interventions
Structured daily diary
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 24 Years · Male only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Aurora, Colorado • Detroit, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Sep 20, 2026, 9:55 AM EDT
Completed Phase 1 Interventional

Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults

NCT00000877
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Rifabutin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
8
States / cities
Los Angeles, California • Denver, Colorado • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 20, 2026, 9:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects

NCT02666053
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 20, 2026, 9:55 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

NCT02289495
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232, Placebo, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 20, 2026, 9:55 AM EDT
Completed Phase 3 Interventional

A Clinical Study of Intravenous Immunoglobulin

NCT00468273
View directory record Official record
Conditions
Immunologic Deficiency Syndromes
Interventions
Immune Globulin Intravenous (Human) Omr-IgG-am IGIV
Drug
Lead sponsor
FFF Enterprises
Industry
Eligibility
3 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
8
States / cities
Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2014 · Synced Sep 20, 2026, 9:55 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effectiveness of Relationship Education for Reducing HIV Incidence Among Men Who Have Sex With Men

NCT05678556
View directory record Official record
Conditions
Hiv, Chlamydia, Gonorrhea
Interventions
all2GETHER
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
16 Years to 34 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 20, 2026, 9:55 AM EDT
Completed Not applicable Interventional

Treatment Program for Anemia in AIDS Patients

NCT00002022
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Epoetin alfa
Drug
Lead sponsor
R W Johnson Pharmaceutical Research Institute
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Raritan, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 20, 2026, 9:55 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

NCT01854775
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
E/C/F/TAF, E/C/F/TAF (Low Dose)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
2 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
5
States / cities
Long Beach, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 20, 2026, 9:55 AM EDT
Completed Not applicable Interventional

Study of Total Body Irradiation and Fludarabine Followed By Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation in Combination With Cyclosporine and Mycophenolate Mofetil in Patients With Inherited Disorders

NCT00010361
View directory record Official record
Conditions
Metabolism, Inborn Errors, Granulomatous Disease, Chronic
Interventions
cyclosporine, fludarabine, mycophenolate mofetil
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Sep 20, 2026, 9:55 AM EDT
Completed Phase 3 Interventional

Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen

NCT00135369
View directory record Official record
Conditions
HIV Infections
Interventions
stavudine extended-release, lamivudine, efavirenz
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
46
States / cities
Hobson City, Alabama • Montgomery, Alabama • Phoenix, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2011 · Synced Sep 20, 2026, 9:55 AM EDT
Completed Phase 2 Interventional

A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects

NCT00075231
View directory record Official record
Conditions
HIV Infections
Interventions
Kaletra® (lopinavir/ritonavir), Combivir® (lamivudine, zidovudine), Sustiva® (efavirenz)
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Fountain Valley, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2006 · Synced Sep 20, 2026, 9:55 AM EDT